Mitomycin C for pterygium: long term evaluation

Br J Ophthalmol. 2004 Nov;88(11):1425-8. doi: 10.1136/bjo.2003.039891.

Abstract

Aim: To evaluate long term complications after pterygium excision with mitomycin C (MMC) application.

Design: Prospective non-comparative interventional case series.

Participants: Ninety nine patients who underwent pterygium surgery and participated in a controlled study for efficacy of MMC for pterygium surgery between 1989 and 1994.

Methods: Patients who were located and agreed to come for examination underwent a complete eye examination. The bare sclera area, in particular, was examined for possible complications. The main outcome measures were anatomical findings in area of MMC application.

Results: Forty three eyes of 43 patients were examined. Sixty three per cent of patients had pterygium surgery with intraoperative application of 0.02% MMC for 5 minutes and 37% of patients received MMC 1% or 2% drops four times daily for 2 weeks postoperatively. In three patients, pterygium recurred within 18 months. The only complication was mild conjunctival avascularity in areas of pterygium excision in 30% of patients.

Conclusion: Long term evaluation revealed that the use of MMC in pterygium surgery is safe, but for a strict selection of patients, controlled use of MMC and long term follow up are required.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Alkylating Agents / adverse effects
  • Alkylating Agents / therapeutic use*
  • Antibiotics, Antineoplastic / adverse effects
  • Antibiotics, Antineoplastic / therapeutic use*
  • Conjunctiva / blood supply
  • Female
  • Humans
  • Intraoperative Care / methods
  • Male
  • Middle Aged
  • Mitomycin / adverse effects
  • Mitomycin / therapeutic use*
  • Postoperative Care / methods
  • Postoperative Complications / prevention & control
  • Prospective Studies
  • Pterygium / drug therapy*
  • Pterygium / prevention & control
  • Pterygium / surgery
  • Secondary Prevention
  • Treatment Outcome

Substances

  • Alkylating Agents
  • Antibiotics, Antineoplastic
  • Mitomycin